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Background: There are no effective medications for the treatment of social cognition/function deficits in autism
spectrum disorder (ASD), and adult intervention literature in this area is sparse. Emerging data from animal models
and genetic association studies as well as early, single-dose intervention studies suggest that the oxytocin system
may be a potential therapeutic target for social cognition/function deficits in ASD. The primary aim of this study
was to examine the safety/therapeutic effects of intranasal oxytocin versus placebo in adults with ASD, with respect
to the two core symptom domains of social cognition/functioning and repetitive behaviors.
Methods: This was a pilot, randomized, double-blind, placebo-controlled, parallel design trial of intranasal oxytocin
versus placebo in 19 adults with ASD (16 males; 33.20 ± 13.29 years). Subjects were randomized to 24 IU intranasal
oxytocin or placebo in the morning and afternoon for 6 weeks. Measures of social function/cognition (the
Diagnostic Analysis of Nonverbal Accuracy) and repetitive behaviors (Repetitive Behavior Scale Revised) were
administered. Secondary measures included the Social Responsiveness Scale, Reading-the-Mind-in-the-Eyes Test and
the Yale Brown Obsessive Compulsive Scale – compulsion subscale and quality of life (World Health Organization
Quality of Life Questionnaire – emotional/social subscales). Full-information maximum-likelihood parameter
estimates were obtained and tested using mixed-effects regression analyses.
Results: Although no significant changes were detected in the primary outcome measures after correcting for
baseline differences, results suggested improvements after 6 weeks in measures of social cognition (Reading-the-
Mind-in-the-Eyes Test, p = 0.002, d = 1.2), and quality of life (World Health Organization Quality of Life
Questionnaire – emotion, p = 0.031, d = 0.84), both secondary measures. Oxytocin was well tolerated and no
serious adverse effects were reported.
Conclusions: This pilot study suggests that there is therapeutic potential to daily administration of intranasal
oxytocin in adults with ASD and that larger and longer studies are warranted.
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Autism spectrum disorder (ASD) is a group of neurodeve-
lopmental disorders characterized by impairments in social
functioning, communication and repetitive behaviors. Cur-
rently, there are no pharmacologic treatments for social
cognition and function deficits in individuals with ASD.
Oxytocin and its related pathways have been of particular
interest in ASD, because of its unique role in influencing
social behaviors and its potential for generating animal
models with behavioral deficits that may be relevant to
ASD [1]. Emerging genetics data from association studies
and few cases with deletions/duplications of the oxytocin
receptor (OXT-R) gene suggest that oxytocin may play a
role in the pathophysiology of the disorder (for example
[2-5]). Additionally, a reduction in oxytocin mRNA has
been reported in the temporal cortex of subjects with ASD
and associated with hypermethylation [3], suggesting
decreased expression of the OXT-R in at least a subgroup
of individuals with ASD. Abnormalities in oxytocin blood
levels have also been reported in this population [6-8].
Oxytocin is a nine-amino-acid peptide, which is
synthesized in the paraventricular and supraoptic nu-
cleus of the hypothalamus and released into the blood-
stream by the posterior pituitary. Oxytocin is also widely
distributed in the central nervous system. Oxytocin has
been shown to play a role in social recognition, memory,
and attachment, as well as in stereotyped behaviors such
as exaggerated grooming [9,10]. Oxytocin knockout mice
exhibit deficits in social recognition, in the context of in-
tact olfaction and cognitive abilities, which were recov-
ered by intraventricular oxytocin [11]. OXT-R knockout
mice produce fewer ultrasonic vocalizations in response
to social isolation than the wild type and exhibit more
aggressive behavior [12]. Sala and colleagues recently
published research on phenotypic characterization of the
OXT-R null mice [13]. They reported that OXT-R null
mice demonstrated resistance to change and susceptibil-
ity to seizures in addition to the social deficits previously
described. Of particular interest, administration of oxy-
tocin restored to normal the social exploration and rec-
ognition deficits.
Human studies of neuropeptide hormones
Methodological difficulties have limited the number of
studies examining the effect of oxytocin on social cogni-
tion and function in typically developing humans. Early
studies showed that intranasal oxytocin (IN-OXT) pro-
motes trust and prosocial behavior in humans [14]. In a
functional magnetic resonance imaging study, partici-
pants received IN-OXT or placebo and viewed fear-in-
ducing, social (angry and fearful faces) and non-social
(threatening scenes) stimuli [15]. Participants receiving
oxytocin showed reduced amygdala activation to social
stimuli more than nonsocial kinds of stimuli, furthersuggesting that oxytocin is mediating human social be-
havior. These findings were then replicated by Domes
and colleagues, who showed that oxytocin attenuates
amygdala response to faces regardless of valence [16]. Of
relevance to autism, Domes and colleagues found that
oxytocin facilitated performance on measures related to
the ability to infer the mental states of others or that
assessed aspects of theory of mind [17]. Another study
found that IN-OXT increases gaze to the eye region of
human faces [18], a finding or particular interest to aut-
ism, since affected individuals often have eye contact
deficits. Improved face identity recognition memory was
reported post 20 IU of IN-OXT administration versus
placebo [19]. Recognition memory was improved for
faces but not objects with IN-OXT versus placebo in a
task where volunteers had to assess previously viewed
faces to be known or unknown, suggesting a selective ef-
fect of oxytocin on social memory [20]. The last two
studies documented social cognitive effects of a single
dose of IN-OXT at 24 hours post administration, a find-
ing suggestive of social learning effects.
Single-dose intranasal oxytocin studies in ASD
In a double-blind, crossover challenge of intravenous
oxytocin versus placebo, intravenous administration of
oxytocin facilitated social learning in patients with ASD
[21]. In 2003, the same authors also reported that ASD
patients showed a significant reduction in repetitive be-
havior following oxytocin versus placebo infusion [22].
Another study randomized 16 adolescents to a crossover
placebo-controlled study of a single dose of IN-OXT (24
IU for 15 to 19 year olds, 18 IU for 12 to 15 year olds)
[23]. The authors showed significant improvements in
the Reading the Mind in the Eyes Task (RMET) with
minimal side effects. Andari and colleagues randomized
13 adults with ASD to a single dose of IN-OXT and
reported that patients exhibited stronger interactions
with the most socially cooperative partner during a ball
game, and reported enhanced feelings of trust [6].
Given that social interaction deficits and repetitive
behaviors are core symptom domains of autism, and that
oxytocin is involved in the regulation of social communi-
cation and repetitive behaviors, oxytocin may present a
therapeutic target for individuals with ASD. The primary
aim of this study was to investigate the safety and poten-
tial therapeutic effects of IN-OXT (Syntocinon; NOVAR-
TIS, Basel, Switzerland) versus placebo in adults with
ASD, with respect to the two core symptom domains of
social cognition/functioning and repetitive behaviors.
Methods
This was a randomized, double-blind, placebo-con-
trolled, parallel design trial of IN-OXT versus placebo in
adults with ASD.
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Participants were recruited through advertisements in
local media. Diagnosis was established using a diagnostic
interview to establish DSM-IV criteria for an ASD sup-
ported by the Autism Diagnostic Observation Schedule
[24] and the Autism Diagnostic Interview – Revised [25]
performed by research-reliable administrators. All eligi-
bility assessments were completely before randomization
into the study. Other inclusion criteria included male
or female outpatients 18 to 60 years of age who had a
Clinician Global Impression (CGI) – severity score ≥4
(moderately ill), were on stable pharmacologic and
nonpharmacologic treatments for at least 3 months,
had a normal physical examination, and with full-scale
IQ >70. Exclusion criteria included prematurity; primary
axis I disorders such as bipolar disorder, psychosis, post-
traumatic stress disorder, schizophrenia, or major depressive
disorder/anxiety disorder; history of significant neurological
disease, including, but not limited to, unstable epilepsy
disorder, known genetic syndromes, or known abnormal
brain magnetic resonance imaging (structural brain
lesions); or evidence or history of malignancy or any
significant hematological, endocrine, cardiovascular
(including any rhythm disorder), respiratory, renal, hepatic,
or gastrointestinal disease. Sexually active women had
to be on two barrier methods of contraception and no
hormonal birth control. Patients unable to tolerate
venipuncture procedures were also excluded.
Participants were assessed for capacity to sign consent
by an independent psychiatrist. Only volunteers with
documented capacity in this fashion were invited to par-
ticipate in the study. These participants signed the
informed consent approved by the Mount Sinai Institu-
tional Review Board and according to the Helsinki
agreement. Participants underwent a comprehensive
medical evaluation, baseline assessments and were ran-
domized by the pharmacy in a one-to-one fashion. All
efficacy assessments were carried out by an independent
evaluator who was blinded to both side effects and
group assignment. All safety evaluations were performed
by a physician who was blinded to group assignment.
Although we are not aware of any characteristic side
effects of IN-OXT, this approach assured that all efficacy
assessments were done by a truly blinded clinician.
Medications
Oxytocin (Syntocinon; NOVARTIS) and placebo were
administered in the form of intranasal spray. Participants
received twice-daily 6 weeks of either 24 IU (six puffs)
oxytocin or placebo, in the morning and early afternoon.
Participants were instructed to sit upright, and take one
puff every 30 seconds, alternating nostrils. All partici-
pants took their first dose in front of the study clinician
to assure correct administration and tolerability. Placebowas normal saline in identical bottles and labels. Partici-
pants were asked to comment on smell and taste after
the first dose. Only one commented on possible smell
and he was randomized to the placebo. A computer-
generated randomization table was created by the re-
search pharmacist and used to randomize participants.
Efficacy and safety assessments
Participants were seen every 2 weeks for CGI – im-
provement ratings, vital signs and adverse event moni-
toring. At each visit participants were assessed using
measures of repetitive behaviors (the Yale Brown Obses-
sive Compulsive Scale (YBOCS) – compulsion subscale
[26]) and the Repetitive Behavior Scale – Revised (RBS-R)
[27]), the first being a well-established outcome measure
for repetitive behaviors and the second being a dimen-
sional, validated measure of repetitive behaviors in ASD.
In the absence of well-validated outcome measures for
social function in this population and this age group, we
used the Social Responsiveness Scale [28]. Blood work
for safety included blood count, electrolytes, liver and
renal function, and osmolality. Safety bloodwork, an
electrocardiogram and weight measurements were done
at baseline and week 6 visits. At baseline and week 6,
participants were administered social cognition/percep-
tion measures that have been shown to change in other
populations or after single-dose oxytocin: the RMET –
Revised [29], and the Diagnostic Analysis of Nonverbal
Accuracy (DANVA-2) [30]. Quality of life was measured
using the World Health Organization Quality of Life
Questionnaire (WHOQOL) – emotional/social subscales
[31]. Primary outcome measures included the CGI – im-
provement, the DANVA paralanguage test and the RBS-
R. The rest of the measures were considered secondary.
The participants used a medication diary to mark
down every time they took the medication. The diary
was reviewed at every visit and the study clinician and
the participant problem-solved together in the case of
missed doses to improve compliance.
Statistical approach
We evaluated all distributions to assess need for data
transformations. We did not find any strong statistical
or visual evidence of distributional concerns and so
no transformations were undertaken. We then used
full-information-maximum likelihood mixed-effects re-
gression models to test the hypothesis of differential
change between the treatment groups across time
(time × group interaction), for all measures except for
CGI – improvement. This approach conforms to intent-
to-treat principles as all randomized subjects are
included in the analysis. Further, for comparisons reach-
ing statistical significance we repeated the analysis using
baseline as a covariate. The CGI – improvement scales
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We therefore used the week 6 Improvement Ratings to
categorize patients as clinically improved (CGI ≤2) or not
(CGI >2). Sixteen of the 19 patients (84%) had data at
week 6. For the remaining three subjects, we imputed
week 6 ratings using expectation-maximization (EM)
methods and the earlier CGI ratings. In all three cases
the imputed ratings were >2 and the patients were classi-
fied as not improved.
For the RBS-R we calculated two scores (higher-order
vs. lower-order repetitive behaviors) in an effort to de-
crease the number of variables analyzed. This is based
on previous factor analysis of the RBS-R that produced
these two factors: higher order (ritualistic, sameness,
compulsive and restricted subscales) and lower order
(stereotypy and self-injury) [32]. This construct has also
been supported by a factor analysis of the YBOCS in aut-
ism [33]. Cohen’s d effect sizes were calculated on
observed scores to provide a sense of size of effect to
guide future work. Given that this is a pilot signal find-
ing study, no corrections for multiple comparisons were
done.
Results
Nineteen adults (16 males and three females, mean age
33.2 ± 13.3 years) (Figure 1) with a diagnosis of high-
functioning autism or Asperger’s disorder (Autism Diag-
nostic Observation Schedule –social + communication,CONSORT Flow
Figure 1 Consort flow diagram.8.17 (3.24); Autism Diagnostic Interview – social, 18.3
(6.3); Autism Diagnostic Interview – communication,
14.2 (6.5); Autism Diagnostic Interview – repetitive, 6
(4.1)) were recruited into a 6-week randomized placebo
controlled trial. Ten participants received oxytocin and
nine received placebo. There were no significant differ-
ences in age (mean (standard deviation): oxytocin, 33.8
(12.7); placebo, 32.9 (14.4); t = 0.14, df = 17, P = 0.88) or
full-scale IQ (mean (standard deviation): oxytocin, 99
(22); placebo, 118 (19); t = 1.94216, df = 16, P = 0.07)
(Table 1).
A full-information maximum-likelihood mixed-effects
regression analysis revealed that participants receiving
oxytocin performed better on several outcome measures
than the placebo group after the 6 weeks of treatment.
Primary outcome measures
There were significant differences in performance on the
RBS-R lower-order behaviors (t = −2.17, df = 16.78, p =
0.045, Cohen’s d effect size = 0.64) but not on the
DANVA or CGI. Although baseline differences were not
statistically significant, they were somewhat large and as
such the analysis was repeated with baseline added as a
covariate. The difference in the RBS-R lower-order beha-
viors was now a trend (t = −1.971, df = 17.18, p =
0.065). For the rest of the measures, co-varying baseline
did not change the conclusions of the analyses. Thirty
percent (3/10) of participants in the oxytocin group were Diagram 
Table 1 Demographic information
Total Oxytocin Placebo
Gender
Male 16 (84%) 9 7
Female 3 (16%) 1 2
Race
Caucasian 14 (73.7%) 7 7
Black 1 (5.2%) 1 0
Hispanic 1 (5.2%) 1 0
Asian 2 (10.5%) 1 1
Other 1 (5.2%) 0 1
Group assignment 10 (52%) 9 (48%)
Age (standard deviation) 33.2 (13.3) 33.8 (12.7) 32.9 (14.4)
IQ (standard deviation) 107 (24) 99 (22) 118 (19)
Data presented as n (%) unless indicated otherwise.
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11% (1/9) of participants in the placebo group were
rated as improved.
Secondary outcome measures
In the analysis of secondary measures, significant
improvements were noted on the RMET – Revised
(t = 3.91, df = 9.01, p = 0.004, Cohen’s d effect size = 1.2)
and the WHOQOL – emotional (t = 2.42, df = 10.89,
p = 0.034, Cohen’s d effect size = 0.84) (Table 2). The
results remained significant for the RMET (t = 4.045,
df = 10, p = 0.002) and the WHOQOL – emotional
(t = 2.43, df = 12.37, p = 0.031). There were no sig-
nificant differences between treatment groups across the
6 weeks seen on the SRS, YBOCS, and RBS-R higher-
order behaviors, and co-varying baseline did not change
the conclusions of the analyses. However, this is a pilot
study and therefore was not powered to detect anything
but very large effect sizes. We are thus reporting all effect
sizes to assist with developing future studies (Table 2).
Oxytocin was well tolerated and no serious adverse
effects were reported (Table 3). In the oxytocin group,
two people reported increased irritability of mild to mod-
erate severity, and two participants reported increased
allergy symptoms. One participant with stable epilepsy
was noted to have staring spells by his wife. The events
were not observed by a physician or at any visit, but the
participant was terminated for caution at week 4. Mild
fatigue, a headache leg shaking and increased energy
were also reported. In the placebo group, there were
reports of cough, depressed mood and fatigue, all mild.
There were two early terminations due to worsening tics
(week 4) and a panic attack in response to use of the
nasal spray (baseline visit). There were no significant or
clinically important differences between oxytocin and
placebo in any of the blood work, including completeblood count, electrolytes, liver/renal function and osmo-
lality, and no abnormal electrocardiograms were reported.
Each cell represents one side effect in one participant,
unless otherwise specified. In addition, all side effects
were mild unless otherwise specified.
Discussion
To our knowledge, this is the first study to employ an
acute treatment trial of daily administration of IN-OXT
in ASD. Although no significant improvements were
noted in the primary outcome measures when control-
ling for baseline differences, 6-week use of IN-OXT ver-
sus placebo resulted in improvements in aspects of
social cognition, repetitive behaviors and emotional well-
being in some, although not all, measures used – sug-
gesting potential therapeutic benefit for IN-OXT in this
population, which needs to be explored in follow-up lar-
ger studies. Further, our study did not report any serious
adverse effects and IN-OXT was well tolerated. Our data
are consistent with previous single-dose studies in indi-
viduals with ASD. Our data are also consistent with re-
cent data from schizophrenia and social anxiety. Feifel
and colleagues published an augmentation study of oxy-
tocin in schizophrenia [34]. In 19 participants with re-
sidual symptoms treated with 40 IU oxytocin versus
placebo, the authors reported that oxytocin significantly
reduced scores on the Negative Symptom Scale in
addition to the Positive Symptom Scale and CGI – im-
provement scale compared with placebo at the 3-week
end point. Oxytocin was well tolerated and no adverse
effects were reported. In a randomized, double-blind,
placebo-controlled trial, Guastella and colleagues admi-
nistered 24 IU oxytocin or a placebo in combination
with exposure therapy to 25 participants who met primary
diagnosis for social anxiety disorder [35]. Participants
administered with oxytocin showed improved positive
evaluations of appearance and speech performance, sug-
gesting that following exposure therapy the administration
of oxytocin improved the mental representations of self.
In this study the documented effects are on social per-
ception (RMET), lower-order repetitive behaviors (RBS-
R) and quality of life as it relates to emotion (WHOQOL
– emotion, patients described an effect of well-being).
There is large debate in the literature about the nature
of central/peripheral effects of oxytocin on cognition/
perception and behavior. Both amygdala and the nucleus
accumbens are rich in OXT-R. The question remains
whether the effects of oxytocin on social function are
related to anxiety, social reward, social perception (for
example, emotion, identity detection) or social cognition
(for example, theory of mind). Evidence exists for each
of these hypotheses. The anxiolytic properties of oxyto-
cin have been well documented for both exogenous and
endogenous release and are mediated by both central
Table 2 Parameter estimates and P values from full-information maximum-likelihood mixed-effects regression analyses
B 6-week B p value Mean (standard deviation) d value
Week 0 Week 6
Social cognition
Primary
DANVA – face 2.33 13.98 0.381 0.33
Oxytocin 32.6 (8.8) 33.5 (6.4)
Placebo 39.1 (8.4) 37.4 (7.4)
DANVA – paralanguage 1.96 11.76 0.351 0.38
Oxytocin 27.8 (5.7) 30.5 (2.7)
Placebo 34.1 (3.0) 35.2 (4.7)
Secondary
RMET – 22% 0.004 1.2
Oxytocin 0.002* 48% (20%) 61% (24%)
Placebo 74% (14%) 63% (12%)
Social function
Primary




SRS 0.58 3.48 0.664 0.34
Oxytocin 92.3 (29.9) 111.4 (13.5)
Placebo 84.5 (23.3) 96.5 (13.0)
Repetitive behaviors
Primary
RBS-R higher order – 4.57 0.301 −0.22
Oxytocin 17.0 (10.6) 17.7 (16.2)
Placebo 20.0 (10.8) 17.8 (13.3)
RBS-R lower order – −2.25 0.045 0.64
Oxytocin 0.065* 5.8 (4.6) 2.4 (2.3)
Placebo 4.9 (3.7) 3.7 (2.6)
Secondary
YBOCS 0.16 0.96 0.220 0.13
Oxytocin 12.0 (3.9) 9.4 (2.9)
Placebo 10.3 (2.5) 8.1 (2.5)
Quality of life
WOQOL – emotional – 9.5% 0.034 0.84
Oxytocin 0.031* 47.8% (16.3%) 59.5% (16.0%)
Placebo 65.2% (12.3%) 63.2% (12.3%)
Means, standard deviations and standardized effect sizes are based on the observed data. B, parameter estimate for the group × treatment interaction showing
the additional increase (or decrease) in the units of the measure for the oxytocin group per week; 6-week B, parameter estimate for the interaction multiplied by
6 to reflect the total differential change of the oxytocin group compared with the placebo group across the 6 weeks of the trial; d, Cohen’s d calculated from
observed scores; pooled standard deviation was used (ClinTools software). For the Reading the Mind in the Eyes Task (RMET), Repetitive Behavior Scale – Revised
(RBS-R) and World Health Organization Quality of Life (WOQOL) the measures were obtained pre and post, thus the parameter estimate reflects only the 6-week
(pre–post) change. CGI, Clinical Global Impression; DANVA, Diagnostic Analysis of Nonverbal Accuracy; OR, odds ratio; SRS, Social Responsiveness Scale WHOQOL;
YBOCS, Yale Brown Obsessive Compulsive Scale. *p values when baseline scores are included as a covariate. Significant results are in bold.
Anagnostou et al. Molecular Autism 2012, 3:16 Page 6 of 9
http://www.molecularautism.com/content/3/1/16








Query absence seizures Worsening tics
Fatigue Panic attack – adverse reaction to





Anagnostou et al. Molecular Autism 2012, 3:16 Page 7 of 9
http://www.molecularautism.com/content/3/1/16and peripheral mechanisms [36]. However, effects on
trust, theory of mind, emotion detection and positive
and negative symptoms of schizophrenia have been re-
peatedly documented. In addition, in studies where the
investigators controlled for anxiety using self-report
measures (for example [16]), oxytocin doses that were
adequate to produce social cognition effects did not
show effects of anxiety. Still, given that the relations be-
tween anxiety, affiliative behaviors and social cognition/
perception are not yet well delineated, this remains an
area of active research.
The effects on repetitive behaviors were interesting,
with no effects observed for higher-order behaviors (for
example, compulsive-like) but improvements noted for
low order behaviors (for example, stereotypy) [32,33],
whereas no effects were noted in a measure that com-
bined both types of behaviors in a single severity score
(YBOCS). The possibility that the lower-order behavior
score may be preferentially capturing pleasure-seeking
repetitive behaviors and differentially responding to oxy-
tocin compared with the higher-order domain, tradition-
ally thought to be similar to the egodystonic behaviors
of obsessive–compulsive disorder, is intriguing and
needs to be examined further. This may be of particular
interest given the paucity of available interventions for
lower-order repetitive behaviors.
Limitations
The effect sizes in our study for social cognition and
function ranged from small/medium to very large. This
was a short-duration (6 weeks), small-sample study and
all such effect sizes need to be viewed with caution.
We acknowledge that our relatively small sample size
resulted in baseline differences, which although not sig-
nificant were large in some of the measures. However,
the effects remained significant for both social cognition
as measured by the RMET and the WHOQOL – emo-
tional subscale after adding baseline scores as a covariateand there was a strong trend noted for improvements in
repetitive behaviors as measured by the lower-order sub-
scale of the RBS-R. In addition, the duration of the study
was only 6 weeks and as such we may have underesti-
mated the potential impact of oxytocin on core symp-
tom domains. Furthermore, the sample size precludes us
from examining the impact of other characteristics such
as IQ and concurrent medications on treatment re-
sponse and safety (Additional file 1). The three female
participants were all premenopausal and on no hormo-
nal contraception, but we did not collect data on the
time of menstrual cycle that may potentially interact
with oxytocin [37]. In addition, no information on rela-
tionship status was collected in this study.
A concern raised about trials of IN-OXT is related to
the very short half-life of IN-OXT in the blood. How-
ever, in the context of documented behavioral effects
lasting several hours to days, it seems that plasma levels
of oxytocin are not related to such effects. Although
much clarity is needed about the mechanism of the be-
havioral effects noted with IN-OXT administration, it is
worth noting that levels of vasopressin in the cerebral
spinal fluid were still rising 4 hours post administration
of a single intranasal dose of the peptide in a cerebral
spinal fluid pharmacokinetic study [38].
Placebo in this study was normal saline. Although the
participants detected no taste/smell for the active com-
pound, normal saline is not the vehicle for intranasal
Syntocinon and future studies should use placebo with
identical inactive ingredients.
Lastly, the study did not follow-up the participants
once the medication had been stopped. Given the animal
literature suggesting that oxytocin promotes neural plas-
ticity changes, we would predict that any effects should
outlast the period of actual administration. Follow-up
studies need to include such a design.
Conclusions
Our pilot study supports the therapeutic potential and
safety of daily administration of IN-OXT for social cog-
nition/function deficits and possibly repetitive behaviors
in adults with ASD. Larger sample studies of longer dur-
ation are required to fully examine these effects.
Additional file
Additional file 1: Concomitant psychotropic medications. Table S1
presents all concomitant medications taken by participants during the
study.
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